Our story
- About us
- Latest
- Centres
Our science
- Mission
  - Discover
  - Develop
  - Deliver
- Approaches
- Explore by
Our people
- Researchers
- Governance
- Latest
  
  Feb 19, 2026
  
  First Group Leaders announced for new dedicated Parkinson's Research Centre
  
  In 2025, the UK DRI partnered with Parkinson’s UK to launch a new £10m research...
  Learn more First Group Leaders announced for new dedicated Parkinson's Research Centre
Our partners
- Partnerships
- Initiatives
- Latest
  
  Jan 01, 2024
  
  Why partner with the UK DRI?
  
  The UK DRI is central to a rich and connected dementia research ecosystem, and we...
  Learn more Why partner with the UK DRI?
Careers
- Join us
  - Vacancies
  - Centres
- Latest
  
  Jan 01, 2024
  
  Why join the UK DRI?
  
  By joining the UK DRI you’ll belong to a team of world-class researchers, technical specialists...
  Learn more Why join the UK DRI?
Public Information
- Information
- Dementias
- Movement conditions

J Natl Cancer Inst

Published Sep 09, 2022

The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.

Authors

Kumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Hiroyuki Arai, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Jay A Moore, Ethan S Sokol, Yu Sunakawa

Read More

Abstract

Chemotherapies have limited efficacy in pancreatic cancer (PC) and biliary tract cancer (BTC), underscoring the need for new regimens. Recently, tumor-agnostic approaches have been developed for some targeted therapies in advanced solid tumors; however, the frequency of alterations by clinical and genomic background is unclear in PC and BTC.

PMID:35583261 | DOI: